-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HcmnpxRLverhkv6OTm4yJbfQqzHB0LAYMpsI4mOfa0xXRTjZEZm6SUeYVCbV/We0 oRcsI+jJ0kWLHGSZMDRv1g== 0000912057-01-524320.txt : 20010719 0000912057-01-524320.hdr.sgml : 20010719 ACCESSION NUMBER: 0000912057-01-524320 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20010718 GROUP MEMBERS: CLAL BIOTECHNOLOGY INDUSTRIES LTD. GROUP MEMBERS: CLAL INDUSTRIES AND INVESTMENTS LTD. GROUP MEMBERS: ELAINE RECANATI GROUP MEMBERS: IDB DEVELOPMENT CORPORATION LTD. GROUP MEMBERS: IDB HOLDING CORP LTD GROUP MEMBERS: JUDITH YOVEL RECANATI GROUP MEMBERS: LEON RECANATI GROUP MEMBERS: OUDI RECANATI SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL RESOURCES INC CENTRAL INDEX KEY: 0000878088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223122182 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-46121 FILM NUMBER: 1684003 BUSINESS ADDRESS: STREET 1: ONE RAM RIDGE RD CITY: SPRING VALLEY STATE: NY ZIP: 10977 BUSINESS PHONE: 9144257100 MAIL ADDRESS: STREET 1: ONE RAM RIDGE RD CITY: SPRING VALLEY STATE: NY ZIP: 10977 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IDB HOLDING CORP LTD CENTRAL INDEX KEY: 0000919593 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 3 DANIEL FRISCH STREET STREET 2: THE TOWER CITY: TEL AVIV ISRAEL BUSINESS PHONE: 2125518881 MAIL ADDRESS: STREET 1: 511 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10017 SC 13D/A 1 a2054480zsc13da.txt SCHEDULE 13D/A ---------------------------- OMB APPROVAL ---------------------------- OMB Number: 3235-0145 Expires: August 31, 1999 Estimated Average Burden Hours per response .. 14.90 ---------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Rule 13d-101 Information to be Included in Statements Filed pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) (AMENDMENT NO. 5) PHARMACEUTICAL RESOURCES, INC. --------------------------------------------------------------------- (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE --------------------------------------------------------------------- (Title of Class of Securities) 717125 10 8 --------------------------------------------------------------------- (CUSIP Number) NITZA EINAN, ADV. CLAL INDUSTRIES AND INVESTMENTS LTD. 3 AZRIELI CENTER, TRIANGLE TOWER TEL AVIV, 67023 TEL: 972-3-6075795 ISRAEL --------------------------------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) JUNE 5, 2001 --------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box |_| NOTE: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 27 pages SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 2 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Clal Biotechnology Industries Ltd. (no U.S. I.D. number) - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 3 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Clal Industries and Investments Ltd. (no U.S. I.D. number) - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 4 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS IDB Development Corporation Ltd. (no U.S. I.D. number) - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 5 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS IDB Holding Corporation Ltd. (no U.S. I.D. number) - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 6 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Leon Recanati - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 7 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Oudi Recanati - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 8 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Judith Yovel Recanati - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION Israel - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. SCHEDULE 13D - ------------------------- ----------------------- CUSIP NO. 717125 10 8 PAGE 9 OF 27 PAGES - ------------------------- ----------------------- - ------------------------------------------------------------------------------- (1) NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS Elaine Recanati - ------------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER (a) /X/ OF A GROUP* (b) / / - ------------------------------------------------------------------------------- (3) SEC USE ONLY - ------------------------------------------------------------------------------- (4) SOURCE OF FUNDS* Not Applicable - ------------------------------------------------------------------------------- (5) CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS / / REQUIRED PURSUANT TO ITEMS 2(D) or 2(E) - ------------------------------------------------------------------------------- (6) CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------- NUMBER OF SHARES (7) SOLE VOTING POWER BENEFICIALLY OWNED BY EACH REPORTING -------------------------------------------------- PERSON WITH (8) SHARED VOTING POWER 0 shares -------------------------------------------------- (9) SOLE DISPOSITIVE POWER -------------------------------------------------- (10) SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- (11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares - ------------------------------------------------------------------------------- (12) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) / / EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------- (13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% - ------------------------------------------------------------------------------- (14) TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. This Amendment No. 5 amends items 2 and 5 of this Statement on Schedule 13D, as previously filed with the Securities and Exchange Commission. Unless otherwise defined in this Amendment No. 5 to Schedule 13D, capitalized terms have the meanings given them in the Schedule 13D as previously filed. Item 2. IDENTITY AND BACKGROUND (a) (b) and (c): On May 28, 1999, Mr. Raphael Recanati died and ceased to be a Reporting Person. Mr. Raphael Recanati's son, Mr. Oudi Recanati, whose address is Quai de L'Ile 3, CH-1204, Geneva, Switzerland, is hereby added as a Reporting Person. Mr. Oudi Recanati's present principal occupation is Chairman, Discount Bank and Trust Company, Geneva, Switzerland. On July 13, 2000, Clal (Israel) Ltd. merged into IDB Development and ceased to be a Reporting Person. Clal Pharm changed its name from Clal Pharmaceutical Industries Ltd. to Clal Biotechnology Industries Ltd. on June 18, 1998. The address of Clal Industries, Clal Pharm, IDB Development and IDB Holding is 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel. As of June 29, 2001, IDB Development owned 71.14% of Clal Industries. As of June 29, 2001, IDB Holding owned 56.4% of IDB Development. Mr. Leon Recanati and Mrs. Judith Yovel Recanati are brother and sister and Mr. Oudi Recanati is their cousin. They are the nephews and niece of Mrs. Elaine Recanati. As of June 29, 2001, companies controlled by Oudi Recanati, Leon Recanati, Judith Yovel Recanati and Elaine Recanati held in the aggregate approximately 51.7% of the voting power and equity of IDB Holding. The name, citizenship, residence or business address, present principal occupation, and the name, principal business and address of each corporation in which such occupation is conducted of each of the executive officers and directors of Clal Industries, Clal Pharm, IDB Holding and IDB Development are set forth on Exhibits 1, 2, 3 and 4 hereof, respectively, and incorporated herein by reference. (d) None of the Reporting Persons has, during the past five years, been convicted in any criminal proceeding, excluding traffic violations and similar misdemeanors. Page 10 of 27 pages (e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. (f) Mr. Oudi Recanati is a citizen of Israel. Item 5. INTEREST IN SECURITIES OF THE ISSUER On July 1, 1998, Clal Pharm sold 1,813,272 shares of Common Stock of the Issuer to Merck at a price of $2 per share, in accordance with the Stock Purchase Agreement, leaving a balance of 500,000 shares of Common Stock owned by Clal Pharm. On June 5, 2001, the Issuer, Merck and Clal Pharm entered into an agreement amending the Stock Purchase Agreement to permit Clal Pharm to immediately sell all of its shares of Common Stock. From June 11, 2001 through June 29, 2001, Clal Pharm sold all of its remaining 500,000 shares of Common Stock of the Issuer. As of June 29, 2001, Clal Pharm, Clal Industries, IDB Holding, IDB Development and the Reporting Persons who are natural persons no longer hold beneficially or of record shares of Common Stock of the Issuer. The following table sets forth the sales of shares of Common Stock made by Clal Pharm from June 11, 2001 through June 29, 2001. All such sales were made in the New York Stock Exchange:
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 11 June 2001 20,000 24.300 12 June 2001 10,000 24.400 12 June 2001 10,000 24.300 13 June 2001 9,800 24.250 13 June 2001 10,000 24.300 13 June 2001 30,000 24.350 13 June 2001 200 24.650 14 June 2001 1,300 24.400 15 June 2001 20,400 24.232 18 June 2001 11,500 24.000 20 June 2001 2,000 23.190 20 June 2001 4,000 23.180 20 June 2001 2,000 23.200 20 June 2001 4,000 23.220 21 June 2001 40,000 24.100 --------------------------------------------------
Page 11 of 27 pages
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 21 June 2001 60,000 24.200 21 June 2001 5,700 24.240 21 June 2001 5,000 24.250 21 June 2001 1,000 24.300 21 June 2001 900 24.350 22 June 2001 25,000 24.200 22 June 2001 2,100 24.250 25 June 2001 20,000 24.650 25 June 2001 20,000 24.600 25 June 2001 700 24.190 25 June 2001 1,200 24.170 25 June 2001 400 24.160 25 June 2001 900 24.150 25 June 2001 20,000 24.050 26 June 2001 16,200 24.200 26 June 2001 200 24.210 26 June 2001 5,100 24.220 26 June 2001 3,300 24.230 26 June 2001 7,100 24.240 26 June 2001 13,800 24.250 26 June 2001 600 24.270 26 June 2001 300 24.300 26 June 2001 9,300 24.340 26 June 2001 1,000 24.350 27 June 2001 20,000 24.150 27 June 2001 13,000 24.200 27 June 2001 200 24.220 27 June 2001 3,300 24.230 27 June 2001 20,000 24.280 27 June 2001 3,500 24.300 27 June 2001 10,000 24.500 27 June 2001 2,800 24.800 27 June 2001 900 24.850 27 June 2001 1,100 24.900 27 June 2001 200 24.960 27 June 2001 300 24.980 27 June 2001 4,700 25.000 27 June 2001 5,000 25.800 27 June 2001 2,400 26.320 27 June 2001 2,100 26.340 27 June 2001 500 26.350 29 June 2001 2,000 27.050 29 June 2001 3,000 27.250 29 June 2001 2,000 27.350 -------------------------------------------------
Page 12 of 27 pages
================================================== NO. OF SHARES PRICE PER DATE SOLD SHARE US$ -------------------------------------------------- 29 June 2001 2,000 27.500 29 June 2001 900 27.750 29 June 2001 100 27.900 29 June 2001 1,000 28.090 29 June 2001 1,000 28.500 29 June 2001 1,000 29.000 29 June 2001 200 29.270 29 June 2001 300 29.390 29 June 2001 500 30.000 29 June 2001 500 30.020 29 June 2001 500 31.000 --------------------------------------------------
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Exhibits 1, 2, 3 and 4 Name, citizenship, business address, present principal occupation and employer of executive officers and directors of (1) Clal Industries, (2) Clal Pharm, (3) IDB Holding and (4) IDB Development Exhibit 5 Agreement dated December, 15, 1999, between Oudi Recanati and IDB Holding authorizing IDB Holding to file this Schedule 13D and any amendment hereto on behalf of Mr. Recanati. Exhibit 6 Agreement dated June 5, 2001, among the Issuer, Merck and Clal Pharm. Page 13 of 27 pages SIGNATURE After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct. Dated: July 18, 2001 CLAL BIOTECHNOLOGY INDUSTRIES LTD. CLAL INDUSTRIES AND INVESTMENTS LTD. IDB DEVELOPMENT CORPORATION LTD. IDB HOLDING CORPORATION LTD. LEON RECANATI OUDI RECANATI JUDITH YOVEL RECANATI ELAINE RECANATI By: IDB HOLDING CORPORATION LTD. By: /s/ James I. Edelson ----------------------------------------------------- James I. Edelson, U.S. Resident Secretary of IDB Holding Corporation Ltd. for itself and on behalf of (i) Clal Biotechnology Industries Ltd., Clal Industries and Investments Ltd., IDB Development Corporation Ltd., Elaine Recanati, Leon Recanati and Judith Yovel Recanati pursuant to the agreements annexed to Amendment No. 4 to the Schedule 13D as exhibits 9-10, 12 and 14-16, as filed and (ii) Oudi Recanati pursuant to the agreement annexed to this Amendment No. 5 to the Schedule 13D as exhibit 5, as filed. Page 14 of 27 pages EX-1 2 a2054480zex-1.txt EXHIBIT 1 Exhibit 1 (Information provided as of June 29, 2001 in response to Items 2 through 6 of Schedule 13D) Executive Officers and Directors of Clal Industries and Investments Ltd. ("Clal Industries") Address is: 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel (citizenship the same as country of residence unless otherwise noted)
Name and Address Position in Clal Principal Occupation - ---------------- ---------------- -------------------- Industries ---------- Leon Recanati Chairman of the Board Chairman of the Board 3 Azrieli Center, and Chief Executive Triangle Tower, Officer of IDB Holding Tel Aviv, Israel Corporation Ltd. ("IDBH") Eliahu Cohen Director Director and Co-Chief 3 Azrieli Center, Executive Officer of Triangle Tower, IDB Development Tel Aviv, Israel Nahum Amit Director Advocate 112 Igal Alon Street Tel Aviv, Israel Richard Armon* Director Chairman of Gmul 9 Mahrel Street Investment Co. Ltd. Tel Aviv, Israel Aviezer Chelouche Director Advocate 41 Beeri Street Tel Aviv, Israel Ariel Carasso Director Director of Moise Carasso 26 Rival Street & Sons Ltd. Tel Aviv, Israel Yosef Genosar Director Partner, ARC (an entity 111 Arlozorov Street involved in Business Tel Aviv, Israel Promotions) Dr. Liora Katzenstein Director President of ISEMI Israel 12A Meskin Street School of Enterprise Tel Aviv, Israel Management & Innovation, branch of Swinburne University of Technologies (Australia) - Center for Innovation and Entrepreneurship World Network
Page 15 of 27 pages
Name and Address Position Principal Occupation - ---------------- -------- -------------------- David Leviatan Director Director of Companies 18 Mendele Street Herzelia, Israel Gurion Meltzer Director Management consultant and 44 Jabotinsky Street Lecturer at academic Tel-Aviv, Israel institutes Meir Shannie President and Chief President and Chief 3 Azrieli Center, Executive Officer Executive Officer (1) Triangle Tower, Tel Aviv, Israel Yecheskel Dovrat Executive Vice Executive Vice President (2) 3 Azrieli Center, President Triangle Tower, Tel Aviv, Israel Yeoshua Agassi V. P. Business 3 Azrieli Center, Development Triangle Tower, Tel Aviv, Israel Nitza Einan General Counsel General Counsel 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel Gil Milner Controller Controller (3) 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel Gonen Bieber** VP of Finance Manager Finance Manager (4) 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel Doron Feinberg Corporate Secretary Corporate Secretary 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel Ilan Amit Internal Auditor Internal Auditor of Clal 3 Azrieli Center, Industries and of subsidiaries Triangle Tower of the Clal Group Tel Aviv, Israel
Page 16 of 27 pages * Mr. Armon is a dual citizen of Israel and Romania. ** Mr. Bieber is a dual citizen of Israel and the Republic of Germany. (1) Mr. Shannie is Director of Clal Pharm. (2) Mr. Dovrat is a Director of Clal Pharm. (3) Mr. Milner is a Director of Clal Pharm. (4) Mr. Bieber is a Director of Clal Pharm. Based on the information provided to the Reporting Persons, except as disclosed below, during the past five years, none of the persons listed above has been convicted, or is subject to a judgment, decree or final order, in any of the legal proceedings enumerated in Items 2 (d) and 2 (e) of Schedule 13D. In March 1997 Mr. Meir Shannie, pleaded guilty in the District Court in Jerusalem, Israel to a criminal charge of violating Israel's Restrictive Trade Practices Law in connection with an insurance cartel, and received a suspended sentence of ten months' imprisonment, which has lapsed, and a fine of New Israel Shekels 150,000 (approximately $37,500). Page 17 of 27 pages EX-2 3 a2054480zex-2.txt EXHIBIT 2 Exhibit 2 (Information provided as of June 29, 2001 in response to Items 2 through 6 of Schedule 13D) Executive Officers and Directors of Clal Biotechnologies Industries Ltd. ("Clal Pharm") Who are not Executive Officers or Directors of Clal Industries Address is: 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel (citizenship the same as country of residence unless otherwise noted)
Name and Address Position Principal Occupation - ---------------- --------- -------------------- David Haselkorn, Ph.D. Chief Executive Chief Executive Officer 3 Azrieli Center, Officer Triangle Tower, Tel Aviv, Israel
Based on the information provided to the Reporting Persons, during the past five years, none of the persons listed above has been convicted, or is subject to a judgment, decree or final order, in any of the legal proceedings enumerated in Items 2 (d) and 2 (e) of Schedule 13D. Page 18 of 27 pages EX-3 4 a2054480zex-3.txt EXHIBIT 3 Exhibit 3 (Information provided as of June 29, 2001 in response to Items 2 through 6 of Schedule 13D) Executive Officers, Directors and Persons Controlling IDB Holding Corporation Ltd. (1) ("IDBH") Address is: 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel (citizenship the same as country of residence unless otherwise noted)
Name and Address Position Principal Occupation - ---------------- --------- -------------------- Haym Carasso Director Joint Managing Director 26 Rival Street of Moise Carasso Sons Ltd. Tel Aviv, Israel Eliahu Cohen Director Director and Co-Chief 3 Azrieli Center, Executive Officer of IDB Triangle Tower, Development Tel Aviv, Israel William M. Davidson Director Chief Executive Officer 2300 Harmon Road of Guardian Industries Auburn Hills, Michigan Corporation Rolando Eisen Director Director of Companies 2A Geiger Street Neveh Avivim, Tel Aviv, Israel Yair Hamburger Director Chairman and Managing 29 Derech Haganim Director of Harel Kfar Shmaryahu, Israel Hamishmar Investments Ltd. Robert J. Hurst Director Vice Chairman of Goldman, 85 Broad Street Sachs & Co., Investment New York, New York Bankers
Page 19 of 27 pages
Name and Address Position Principal Occupation - ---------------- --------- -------------------- Dalia Lev Director Director and Co-Chief 3 Azrieli Center, Executive Officer of IDB Triangle Tower, Development Tel Aviv, Israel Solomon Merkin Director Vice President, Leib 910 Sylvan Avenue, Merkin, Inc. (Investments) Suite 130 Englewood Cliffs, New Jersey Raphael Molho Director Director of Companies (2) 22 Ibn Gvirol Street Jerusalem, Israel Lenny Recanati Director Senior Vice President of 3 Azrieli Center, Discount Investment Triangle Tower, Corporation Ltd. Tel Aviv, Israel Leon Recanati Chairman of the Chairman of the Board and 3 Azrieli Center, Board and Chief Chief Executive Officer Triangle Tower, Executive Officer of IDBH and Chairman of Tel Aviv, Israel the Board of Clal Industries (3) Oudi Recanati Director Chairman, Discount Bank Quai de L'ile 3, CH-1204 and Trust Company (4) Geneva, Switzerland Meir Rosenne Director Lawyer 14 Aluf Simhony Street Jerusalem, Israel Israel Zang Director Professor of Management, 10 Kissufim Street Tel Aviv University Tel Aviv, Israel Israel Yovel Director Senior Physician 64 Kaplan Street Tel Aviv Medical Center Herzliya, Israel
Page 20 of 27 pages
Name and Address Position Principal Occupation - ---------------- --------- -------------------- Judith Yovel Recanati Housewife 64 Kaplan Street Herzliya, Israel Elaine Recanati Housewife 23 Shalva Street Herzliya, Israel (citizen of the United States) Zehavit Joseph* Executive Vice Executive Vice 3 Azrieli Center, President and President and Chief Triangle Tower, Chief Financial Financial Officer of IDBH (5) Tel Aviv, Israel Officer Rina Cohen Controller Controller of IDBH (6) 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel Arthur Caplan** Secretary Secretary of IDBH (7) 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel James I. Edelson U.S. Resident Executive Vice President 511 Fifth Avenue Secretary of Overseas Discount New York, New York Corporation, Investments
* Ms. Joseph is a dual citizen of Israel and the United States. ** Mr. Caplan is a dual citizen of Israel and Great Britain. (1) As of June 29, 2001, IDB Holding Corporation Ltd., an Israeli corporation located at 3 Azrieli Center, Triangle Tower, Tel Aviv, Israel, owned approximately 56.4% of the outstanding shares of IDB Development Corporation Ltd. As of such date, companies controlled by Oudi Recanati, Leon Recanati, Judith Yovel Recanati and Elaine Recanati held in the aggregate approximately 51.7% of the voting power and equity of IDB Holding Corporation Ltd. Page 21 of 27 pages (2) Mr. Molho is a Director of IDB Development. (3) Mr. Leon Recanati is Chairman of IDB Development. (4) Mr. Oudi Recanati is Director of IDB Development and is a citizen of Israel. (5) Ms. Joseph is Executive Vice President and Chief Financial Officer of IDB Development. (6) Mrs. Cohen is Controller of IDB Development. (7) Mr. Caplan is Secretary of IDB Development. Based on the information provided to the Reporting Persons, during the past five years, none of the persons listed above has been convicted, or is subject to a judgment, decree or final order, in any of the legal proceedings enumerated in Items 2 (d) and 2 (e) of Schedule 13D. Page 22 of 27 pages EX-4 5 a2054480zex-4.txt EXHIBIT 4 Exhibit 4 (Information provided as of June 29, 2001 in response to Items 2 through 6 of Schedule 13D) Executive Officers and Directors of IDB Development Corporation Ltd. who are not Executive Officers or Directors of IDB Holding Corporation Ltd. Address is: 3 Azrieli Center, Triangle Tower, Tel Aviv 67023, Israel (citizenship is Israel, unless otherwise noted)
Name and Address Position Principal Occupation - ---------------- --------- -------------------- Abraham Ben Joseph Director Director of Companies 87 Haim Levanon Street Ramat Aviv Tel Aviv, Israel Avishay Braverman Director President of Ben Gurion 11 Jericho Street University of the Negev Beer Sheva, Israel Yoel Carasso Director Director of Companies 33 Maaleh Habanim Ramat Gan, Israel Arnon Gafny Director Economist 55 Moshe Kol Street Jerusalem, Israel Michael Levi Director President, Nilit, Ltd. Textile Fashion Ctr. 2 Kaufman Street Tel Aviv, Israel Michael A. Recanati* Director Chairman of Orama Partners, Inc., 590 Fifth Avenue Investment Banking Services New York, New York Avi Shani Vice President, Vice President, 3 Azrieli Center, Investments and Investments and Triangle Tower Chief Economist Chief Economist Tel Aviv, Israel
* Mr. Recanati is a dual citizen of the United States and Israel. Based on information provided to the Reporting Persons, during the past five years, none of the persons listed above has been convicted, or is subject to a judgment, decree or final order, in any of the legal proceedings enumerated in Items 2(d) and 2(e) of Schedule 13D. Page 23 of 27 pages EX-5 6 a2054480zex-5.txt EXHIBIT 5 EXHIBIT 5 December 15, 1999 IDB Holding Corporation Ltd. The Tower 3 Daniel Frisch Street Tel Aviv, Israel 64731 Gentlemen: Pursuant to rule 13d-1(k) (1) (iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees that IDB Holding Corporation Ltd. ("IDB Holding") may file as necessary on behalf of the undersigned with the Securities and Exchange Commission a Schedule 13D or a Schedule 13G and any amendments thereto in respect of shares of the companies listed on Exhibit A hereto purchased, owned or sold from time to time by the undersigned. IDB Holding is hereby authorized to file a copy of this letter as an exhibit to any of said Schedule 13Ds or Schedule 13Gs or any amendments thereto. Very truly yours, /s/ Oudi Recanati -------------------------------------- Oudi Recanati Agreed: IDB Holding Corporation Ltd. By: /s/ James I. Edelson ------------------------------------ James I. Edelson U.S. Resident Corporate Secretary Page 24 of 27 pages Exhibit A American Israeli Paper Mills Ltd. BVR Systems (1998) Ltd. BVR Technologies Ltd. Carmel Container Systems Limited ECI Telecom Ltd. Fundtech Ltd. Nexus Telocation Systems Ltd. Orckit Communications Ltd. Pharmaceutical Resources, Inc. Page 25 of 27 pages EX-6 7 a2054480zex-6.txt EXHIBIT 6 EXHIBIT 6 PHARMACEUTICAL RESOURCES INC. One Ram Ridge Spring Valley, New York 10977 June 5, 2001 Clal Biotechnology Industries Ltd. ("Clal") (previously Clal Pharmaceutical Industries Ltd.) 3 Azrieli Center, 45th Floor TEL-AVIV 67023, ISRAEL Gentlemen, 1. You are hereby released from your obligations under Sections 2 and 4 of a letter agreement by and among Clal, Pharmaceutical Resources, Inc. ("PRI") and Merck KGaA ("Merck") dated March 25, 1998 (the "Agreement"). Clal is permitted to sell up to the 500,000 shares of Common Stock of PRI referred to in Section 2 (a) of the Agreement (the "Tranche C Shares") to third parties under the conditions specified in Sections 2 and 3 herein (the "Sale"). 2. The Sale shall be at a price for each share of PRI which shall not be lower than USD 0.75 below the closing price on the New York Stock Exchange on the last trading day preceding the date of any Sale. 3. Clal will endeavor to arrange 50% of the Sales through Bear, Stearns & Co. Inc. and its affiliates and 50% of the Sales through UBS AG and its affiliates. 4. The undersigned parties agree and represent that there are no shareholders or other agreements, undertakings or restrictions in connection with the Tranche C Shares, other than the Agreement and the agreements specified therein, if any. 5. The Agreement shall automatically terminate in regard to such number of the Tranche C Shares sold in the Sale ("Sold Shares") with no further obligations, liabilities or rights on the part of the parties thereunder in regard to such shares. 6. The Agreement shall remain in full force and effect and binding upon the parties thereunder, under it original terms, in regard to all of the Tranche C Shares which do not constitute any of the Sold Shares. 7. Clal shall have the right, at is sole discretion, to effect or refrain from effecting the Sale in whole or in part. 8. This letter shall constitute an amendment to the Agreement in accordance with Section 11 of the Agreement. Sincerely, Pharmaceutical Resources, Inc. By /s/ Kenneth I. Sawyer ----------------------------- Page 26 of 27 pages Name: Kenneth I. Sawyer Title: President and CEO June 5, 2001 Letter to Clal Biotechnology Industries Ltd. Page 2 of 2 ACCEPTED AND AGREED TO: MERCK KGaA By /s/ Mike Urwin by attorney-in-fact Kenneth Sawyer -------------------------------------------------- Name: Mike Urwin by attorney-in-fact Kenneth Sawyer Title: ACCEPTED AND AGREED TO: Clal Biotechnology Industries Ltd. By /s/ Y. Dovrat and G. Milner --------------------------------------------------- Name: Y. Dovrat, G. Milner Title: Page 27 of 27 pages -----END PRIVACY-ENHANCED MESSAGE-----